The biopharmaceutical company, Servatus, is dedicated to developing safe and reliable microbiome-based therapeutic drugs for select autoimmune, gastrointestinal, and dermatological conditions. Their approach involves engineering "intelligent" directed changes into the structure of select proteins to improve their clinical utility. Servatus has isolated and characterized select microbial species and undertaken extensive pre-clinical investigations to develop defined medicines that address inflammatory conditions and bacterial infections. Their goal is to provide healthcare providers with first-line and adjunct treatments for chronic and inflammatory diseases, with a particular focus on auto-immune diseases.